Thibault Raoult
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thibault Raoult has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Aurelien Marabelle
University of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France
19 shared publications Siham Farhane
INSERM CIC 1428, BIOTHERIS, Villejuif, France
15 shared publicationsChristophe Massard
Université Paris Saclay, Faculty of Medicine, Villejuif, France
14 shared publicationsJean-Charles Soria
Université Paris Saclay, Faculty of Medicine, Villejuif, France
14 shared publicationsCaroline Robert
13 shared publications- Lambros Tselikas
Département d’Anesthésie, Chirurgie et Interventionnel (DACI), Service de Radiologie Interventionnelle, Gustave Roussy, Villejuif, France
13 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by Springer Nature in Nature
- Vol. 655 (8121) , 219-229
Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1
Intravenous administration of anti-CTLA4 with anti-PD1 provides durable tumour responses but causes severe treatment-related adverse events in patients with cancer 1 . Intratumoural administration at lower doses but high local concentrations could enhance antitumour efficacy while minimizing systemic exposure and toxicity. Here we report the randomized multicentre phase 1b NIVIPIT trial (ClinicalTrials.gov: NCT02857569 ), which enrolled 61 patients with untreated metastatic melanoma, randomly assigned 2:1 to receive intravenous nivolumab (anti-PD1; 1 mg kg −1 ) combined with either intratumoural ipilimumab (anti-CTLA4; 0.3 mg kg −1 ) or intravenous ipilimumab (3 mg kg −1 ). The primary end-point was met with significantly lower incidence of grade 3 or 4 treatment-related adverse events at 6 months in the intratumoural versus intravenous arm (22.6% versus 57.1%), equivalent to anti-PD1 monotherapy. RECIST (response evaluation criteria in solid tumours) best objective response rate reached 65.7% for anti-CTLA4 injected lesions and 50% for uninjected lesions, confirming the relationship between intratumoural exposure to anti-CTLA4 and efficacy. Baseline tumour immune profiling revealed that protumoural activated regulatory T (T reg ) cells and M2 macrophages predict durable clinical benefit, regardless of the anti-CTLA4 administration route. A decrease in activated intratumoural T reg cells occurred only in patients who showed durable clinical benefit, who also presented high intratumoural Fcγ receptor (FcγR) expression. Our results provide a rationale for intratumoural anti-CTLA4 strategies in oligometastatic and early-stage cancers and indicate that high intratumoural activated T reg cell and FcγR + M2 macrophage numbers are prerequisites for efficacy of combined anti-CTLA4 and anti-PD1.
- 29 April 2026
- Published by Springer Nature in Nature
- Vol. 655 (8121) , 219-229
Open AccessSafety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1
Intravenous administration of anti-CTLA4 with anti-PD1 provides durable tumour responses but causes severe treatment-related adverse events in patients with cancer 1 . Intratumoural administration at lower doses but high local concentrations could enhance antitumour efficacy while minimizing systemic exposure and toxicity. Here we report the randomized multicentre phase 1b NIVIPIT trial (ClinicalTrials.gov: NCT02857569 ), which enrolled 61 patients with untreated metastatic melanoma, randomly assigned 2:1 to receive intravenous nivolumab (anti-PD1; 1 mg kg −1 ) combined with either intratumoural ipilimumab (anti-CTLA4; 0.3 mg kg −1 ) or intravenous ipilimumab (3 mg kg −1 ). The primary end-point was met with significantly lower incidence of grade 3 or 4 treatment-related adverse events at 6 months in the intratumoural versus intravenous arm (22.6% versus 57.1%), equivalent to anti-PD1 monotherapy. RECIST (response evaluation criteria in solid tumours) best objective response rate reached 65.7% for anti-CTLA4 injected lesions and 50% for uninjected lesions, confirming the relationship between intratumoural exposure to anti-CTLA4 and efficacy. Baseline tumour immune profiling revealed that protumoural activated regulatory T (T reg ) cells and M2 macrophages predict durable clinical benefit, regardless of the anti-CTLA4 administration route. A decrease in activated intratumoural T reg cells occurred only in patients who showed durable clinical benefit, who also presented high intratumoural Fcγ receptor (FcγR) expression. Our results provide a rationale for intratumoural anti-CTLA4 strategies in oligometastatic and early-stage cancers and indicate that high intratumoural activated T reg cell and FcγR + M2 macrophage numbers are prerequisites for efficacy of combined anti-CTLA4 and anti-PD1.
- Open Access
- 20 August 2025
- Published by Springer Nature in Research Square
Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1
Intravenous anti-CTLA4 with anti-PD1 provides durable tumor responses but generates high rates of severe immune-related adverse events (irAEs) in cancer patients1-3. As opposed to anti-PD1 antibodies, anti-CTLA4 efficacy and toxicity is dose dependent, which limits its use in many patients and restricts broader application, particularly in localized cancers. Therefore, administering lower doses of anti-CTLA4 but directly into tumors and at high local concentrations could enhance anti-tumor efficacy while minimizing systemic exposure and toxicity. Conversely, stronger activation of tumor infiltrating lymphocytes could increase systemic toxicity in case of cross-reactivity with healthy tissue antigens. To challenge those hypothesis we launched a randomized multicenter Phase 1b NIVIPIT trial (NCT02857569), where 61 patients untreated metastatic melanoma patients were randomly assigned 2:1 to receive intravenous nivolumab (1mg/kg) in combination with either intratumoral (IT) ipilimumab (0.3mg/kg) or intravenous (IV) ipilimumab (3mg/kg). The primary endpoint was met with a significantly lower incidence of grade ≥ 3 irAEs at 6 months in the IT arm vs the IV arm (22.6% vs 57.1%), equivalent to anti-PD1 monotherapy, thereby demonstrating the safety of this approach. The RECIST 1.1 best objective response rate was 65.7% for anti-CTLA4 injected tumor lesions, and 50% for the non-injected lesions demonstrating an increased efficacy upon intratumoral anti-CTLA4 therapy. Baseline tumor immune profiling revealed that, unexpectedly, protumoral activated Tregs and M2 macrophages, were alongside HLA-I & II mediated adaptive T- & B-cells anti-tumor immunity predicting durable clinical benefit regardless of the anti-CTLA4 administration route. Upon anti-CTLA4 + anti-PD1 immunotherapy, intratumoral activated Tregs decrease and tumor-secreted Granzymes increase was found only in patients with durable clinical benefit. Our results provide the rationale for developing intratumoral anti-CTLA4 immunotherapy strategies in oligo-metastatic and earlier-stage cancers to avoid toxicities and suggest that persisting intratumoral regulatory–effector immune interface with high Tregs and M2 macrophages is a pre-requisite for anti-CTLA- 4 + anti-PD1 efficacy. Trial registration: ClinicalTrials.gov Identifier, NCT 02857569
- 20 August 2025
- Published by Springer Nature in Research Square
Open AccessSafety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1
Intravenous anti-CTLA4 with anti-PD1 provides durable tumor responses but generates high rates of severe immune-related adverse events (irAEs) in cancer patients1-3. As opposed to anti-PD1 antibodies, anti-CTLA4 efficacy and toxicity is dose dependent, which limits its use in many patients and restricts broader application, particularly in localized cancers. Therefore, administering lower doses of anti-CTLA4 but directly into tumors and at high local concentrations could enhance anti-tumor efficacy while minimizing systemic exposure and toxicity. Conversely, stronger activation of tumor infiltrating lymphocytes could increase systemic toxicity in case of cross-reactivity with healthy tissue antigens. To challenge those hypothesis we launched a randomized multicenter Phase 1b NIVIPIT trial (NCT02857569), where 61 patients untreated metastatic melanoma patients were randomly assigned 2:1 to receive intravenous nivolumab (1mg/kg) in combination with either intratumoral (IT) ipilimumab (0.3mg/kg) or intravenous (IV) ipilimumab (3mg/kg). The primary endpoint was met with a significantly lower incidence of grade ≥ 3 irAEs at 6 months in the IT arm vs the IV arm (22.6% vs 57.1%), equivalent to anti-PD1 monotherapy, thereby demonstrating the safety of this approach. The RECIST 1.1 best objective response rate was 65.7% for anti-CTLA4 injected tumor lesions, and 50% for the non-injected lesions demonstrating an increased efficacy upon intratumoral anti-CTLA4 therapy. Baseline tumor immune profiling revealed that, unexpectedly, protumoral activated Tregs and M2 macrophages, were alongside HLA-I & II mediated adaptive T- & B-cells anti-tumor immunity predicting durable clinical benefit regardless of the anti-CTLA4 administration route. Upon anti-CTLA4 + anti-PD1 immunotherapy, intratumoral activated Tregs decrease and tumor-secreted Granzymes increase was found only in patients with durable clinical benefit. Our results provide the rationale for developing intratumoral anti-CTLA4 immunotherapy strategies in oligo-metastatic and earlier-stage cancers to avoid toxicities and suggest that persisting intratumoral regulatory–effector immune interface with high Tregs and M2 macrophages is a pre-requisite for anti-CTLA- 4 + anti-PD1 efficacy. Trial registration: ClinicalTrials.gov Identifier, NCT 02857569
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale.Significance:In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli–specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies.This article is highlighted in the In This Issue feature, p. 2221
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale.Significance:In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli–specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies.This article is highlighted in the In This Issue feature, p. 2221
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale.Significance:In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli–specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies.This article is highlighted in the In This Issue feature, p. 2221
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale.Significance:In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli–specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies.This article is highlighted in the In This Issue feature, p. 2221
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Interventional Radiology for Local Immunotherapy in Oncology
Angular error impact on accuracy according to tumor size and depth
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Interventional Radiology for Local Immunotherapy in Oncology
Angular error impact on accuracy according to tumor size and depth
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Interventional Radiology for Local Immunotherapy in Oncology
Devices for direct intratumoral immunotherapy
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Interventional Radiology for Local Immunotherapy in Oncology
Devices for direct intratumoral immunotherapy
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Interventional Radiology for Local Immunotherapy in Oncology
Techniques to tag the injected tumor
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Interventional Radiology for Local Immunotherapy in Oncology
Techniques to tag the injected tumor
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Interventional Radiology for Local Immunotherapy in Oncology
Human intratumoral immunotherapy (HIT-IT) is under rapid development, with promising preliminary results and high expectations for current phase III trials. While outcomes remain paramount for patients and the referring oncologists, the technical aspects of drug injection are critical to the interventional radiologist to ensure optimal and reproducible outcomes. The technical considerations for HIT-IT affect the safety, efficacy, and further development of this treatment option. Image-guided access to the tumor allows the therapeutic index of a treatment to be enhanced by increasing the intratumoral drug concentration while minimizing its systemic exposure and associated on-target off-tumor adverse events. Direct access to the tumor also enables the acquisition of cancer tissue for sequential sampling to better understand the pharmacodynamics of the injected immunotherapy and its efficacy through correlation of immune responses, pathologic responses, and imaging tumor response. The aim of this article is to share the technical insights of HIT-IT, with particular consideration for patient selection, lesion assessment, image guidance, and technical injection options. In addition, the organization of a standard patient workflow is discussed, so as to optimize HIT-IT outcome and the patient experience.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Interventional Radiology for Local Immunotherapy in Oncology
Human intratumoral immunotherapy (HIT-IT) is under rapid development, with promising preliminary results and high expectations for current phase III trials. While outcomes remain paramount for patients and the referring oncologists, the technical aspects of drug injection are critical to the interventional radiologist to ensure optimal and reproducible outcomes. The technical considerations for HIT-IT affect the safety, efficacy, and further development of this treatment option. Image-guided access to the tumor allows the therapeutic index of a treatment to be enhanced by increasing the intratumoral drug concentration while minimizing its systemic exposure and associated on-target off-tumor adverse events. Direct access to the tumor also enables the acquisition of cancer tissue for sequential sampling to better understand the pharmacodynamics of the injected immunotherapy and its efficacy through correlation of immune responses, pathologic responses, and imaging tumor response. The aim of this article is to share the technical insights of HIT-IT, with particular consideration for patient selection, lesion assessment, image guidance, and technical injection options. In addition, the organization of a standard patient workflow is discussed, so as to optimize HIT-IT outcome and the patient experience.